These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3935135)

  • 21. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of the in vitro effect of ceftazidime and 12 other antibiotics on gram-negative bacteria isolated from a hospital environment].
    Goglio A; Obiso D; Donadini C; Perani V
    G Ital Chemioter; 1984; 31(3):219-22. PubMed ID: 6442982
    [No Abstract]   [Full Text] [Related]  

  • 24. Antimicrobial resistance and minimum inhibitory concentrations of bacteria isolated from bustards in the United Arab Emirates.
    Bailey TA; Silvanose C; Wernery U; Samour JH; Naldo J
    Avian Dis; 1998; 42(4):690-7. PubMed ID: 9876837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of aztreonam, cefuroxime and ceftazidime against gram-negative rods isolated from hospital patients with urinary tract infection.
    Webb G; Robbins MJ; O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Int J Clin Pharmacol Res; 1987; 7(3):203-5. PubMed ID: 3298085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Resistance of causative agents of uncomplicated urinary tract infections in Russia].
    Rafal'skiĭ VV; Strachunskiĭ LS; Babkin PA; Valenskaia VS; Gabbasova LA; Dmitrieva OB; Emel'ianova IV; Krupin VN; Malev IV; Petrov SB; Rokhlikov IM; Furletova NM; Khaĭrullov AS
    Urologiia; 2006; (5):34-7. PubMed ID: 17444150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats.
    Coulet M; Cox P; Lohuis J
    J Vet Pharmacol Ther; 2005 Feb; 28(1):29-36. PubMed ID: 15720512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effect of Gram-negative and Gram-positive microorganisms against Helicobacter pylori clinical isolates.
    López-Brea M; Alarcón T; Domingo D; Díaz-Regañón J
    J Antimicrob Chemother; 2008 Jan; 61(1):139-42. PubMed ID: 17965421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1-Chloropiperazinic derivative (ER 311) of norfloxacin: antibacterial activity in vitro and pharmacokinetic properties in mice.
    Dubini F; Balsari A; Stradi R; Riviera L
    Chemioterapia; 1987 Jun; 6(2 Suppl):178-80. PubMed ID: 3509385
    [No Abstract]   [Full Text] [Related]  

  • 32. Susceptibility of clinical isolates of gram-positive and gram-negative organisms to cefatrizine.
    Carlone NA; Cuffini AM; Forno Pizzoglio M; Cavallo G
    Drugs Exp Clin Res; 1985; 11(7):447-51. PubMed ID: 3836867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial activity and pharmacokinetics in mice of two new derivatives of norfloxacin.
    Balsari A; Dubini F; Stradi R; Riviera L
    Chemioterapia; 1987 Jun; 6(2 Suppl):176-8. PubMed ID: 3509384
    [No Abstract]   [Full Text] [Related]  

  • 34. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activity of eight antibiotics against Pseudomonas aeruginosa and infrequently isolated gram-negative bacilli.
    Chiaradia V; Pascoli L; Santini G
    Chemioterapia; 1985 Aug; 4(4):284-8. PubMed ID: 3931923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections].
    Grosset J
    Pathol Biol (Paris); 1990 Sep; 38(7):735-41. PubMed ID: 2235090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of urinary infection with cephadroxyl (Pharmachem)--microbiological and clinical research].
    Minkov N; Zlatanov Z; Zozikov B; Khristova D
    Vutr Boles; 1987; 26(5):98-104. PubMed ID: 3433735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occurrence of gram negative bacteria in midstream bladder urine and their sensitivity to quinoline derivatives.
    Esposito S; Galante D; Pennucci C; Barba D
    Microbiologica; 1985 Jul; 8(3):269-76. PubMed ID: 3162081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Influence of technical factors in the determination of minimal inhibitory concentration by microdilution].
    Forey F; Coulet M; Brun Y; Fleurette J
    Pathol Biol (Paris); 1985 May; 33(5):341-9. PubMed ID: 3162138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Statistical studies on bacteria isolated from urinary tract infections (report 4)].
    Okada K; Nakajima N; Kawashima T; Miyakita H; Nishizawa K; Shiramizu M; Nagata Y; Katsuoka Y; Kinoshita H; Kawamura N
    Hinyokika Kiyo; 1987 Jul; 33(7):1080-91. PubMed ID: 3687632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.